Implantable automatic burst tachycardia-terminating pacemakers successfully terminated drug-refractory sustained ventricular tachycardia in two patients over a follow-up of up to 5.5 years.
Case Report (n=2)
Do implantable automatic burst tachycardia-terminating ventricular pacemakers effectively terminate ventricular tachycardia in patients with drug-refractory sustained VT?
Implantable automatic burst pacemakers demonstrated long-term efficacy in terminating drug-refractory sustained ventricular tachycardia.
This report describes the long-term follow-up of two patients who received implantable automatic burst tachycardia-terminating ventricular pacemakers for the treatment of drug-refractory sustained ventricular tachycardia. After implantation, both pulse generators continued to terminate ventricular tachycardia without any major complications. In one patient, after three years, many episodes of ventricular tachycardia were slower than the tachycardia-detection criterion rate of 137 per minute; ventricular tachycardia was then terminated by chest wall stimulation that activated the burst function of the pacemaker. In this particular patient, the pulse generator was removed after four and one-half years and replaced with a DDD system because of the pacemaker syndrome and attacks of ventricular tachycardia, often at a rate of about 100/minute. In the second patient, the pacemaker continued to terminate ventricular tachycardia for over five and one-half years as determined by the repeated activation of the flag (memory) function of the pacemaker indicating detection of tachycardia by the pulse generator and resultant delivery of burst pacing.
Falkoff et al. (Sat,) conducted a case report in drug-refractory sustained ventricular tachycardia (n=2). implantable automatic burst tachycardia-terminating ventricular pacemakers was evaluated on termination of ventricular tachycardia. Implantable automatic burst tachycardia-terminating pacemakers successfully terminated drug-refractory sustained ventricular tachycardia in two patients over a follow-up of up to 5.5 years.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: